TipRanks
Ligand Pharma (DE:LGDN)
FRANKFURT:LGDN
Germany Market
LGDN
Ligand Pharma
RESEARCH TOOLSreports

Ligand Pharma (LGDN) Stock Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

LGDN Analyst Ratings

Strong Buy
9Ratings
Strong Buy
9 Buy
0 Hold
0 Sell
Based on 9 analysts giving stock ratings to
Ligand
Pharma
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

LGDN Stock 12 Month Forecast

Average Price Target

€317.00
▲(34.32% Upside)
Based on 9 Wall Street analysts offering 12 month price targets for Ligand Pharma in the last 3 months. The average price target is €317.00 with a high forecast of €353.23 and a low forecast of €290.06. The average price target represents a 34.32% change from the last price of €236.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"147":"€147","354":"€354","198.75":"€198.8","250.5":"€250.5","302.25":"€302.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":353.22673236,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€353.23</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":317.0016086742857,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€317.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":290.05520088,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€290.06</span>\n  </div></div>","useHTML":true}}],"tickPositions":[147,198.75,250.5,302.25,354],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,268,274.5559024892308,281.1118049784615,287.6677074676923,294.2236099569231,300.77951244615383,307.3354149353846,313.8913174246154,320.4472199138462,327.00312240307693,333.5590248923077,340.11492738153845,346.67082987076924,{"y":353.22673236,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,268,271.7693545134066,275.5387090268132,279.3080635402198,283.0774180536264,286.846772567033,290.6161270804396,294.3854815938461,298.1548361072527,301.9241906206593,305.6935451340659,309.4628996474725,313.2322541608791,{"y":317.0016086742857,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,268,269.6965539138462,271.3931078276923,273.08966174153846,274.7862156553846,276.48276956923075,278.1793234830769,279.87587739692304,281.5724313107692,283.2689852246154,284.9655391384615,286.6620930523077,288.3586469661538,{"y":290.05520088,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":148,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":159,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":167,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":164,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":162,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":166,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":169,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":188,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":192,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":262,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":250,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":242,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":268,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€353.23Average Price Target€317.00Lowest Price Target€290.06
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on DE:LGDN
Glen Santangelo
Barclays
Barclays
€306.96
Buy
30.07%
Upside
Initiated
09/25/26
Analysts Offer Insights on Healthcare Companies: Ligand Pharma (NASDAQ: LGND), Natera (NASDAQ: NTRA) and Aveanna Healthcare Holdings (NASDAQ: AVAH)
H.C. Wainwright Analyst forecast on DE:LGDN
Joseph Pantginis
H.C. Wainwright
H.C. Wainwright
€318.53
Buy
34.97%
Upside
Reiterated
09/24/26
Wainwright sees upside in Ligand after new CAR-T investment in AvenCell Wainwright sees upside in Ligand after new CAR-T investment in AvenCell
Craig-Hallum Analyst forecast on DE:LGDN
Matt Hewitt
Craig-Hallum
Craig-Hallum
―
Buy
―
Assigned
09/24/26
Analysts' Top Healthcare Picks: Ligand Pharma (LGND), Mediwound (MDWD)
Citi Analyst forecast on DE:LGDN
Yigal Nochomovitz
Citi
Citi
€347→€353.23
Buy
49.67%
Upside
Reiterated
09/23/26
Ligand price target raised to $397 from $390 at CitiLigand price target raised to $397 from $390 at Citi
Stifel Nicolaus Analyst forecast on DE:LGDN
Annabel Samimy
Stifel Nicolaus
Stifel Nicolaus
―
Buy
―
Reiterated
09/22/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (NASDAQ: AMGN), Ligand Pharma (NASDAQ: LGND) and Compass Therapeutics (NASDAQ: CMPX)
Bank of America Securities Analyst forecast on DE:LGDN
Jason Zemansky
Bank of America Securities
Bank of America Securities
€345.22
Buy
46.28%
Upside
Reiterated
09/22/26
Analyst Reiterates Buy on Ligand as Ryjunea Royalty Deal Highlights Disciplined Capital Deployment and Supports Unchanged $388 Price Target
RBC Capital Analyst forecast on DE:LGDN
Douglas Miehm
RBC Capital
RBC Capital
€306.96
Buy
30.07%
Upside
Reiterated
08/09/26
Ligand Pharma (LGND) Gets a Buy from RBC Capital
Oppenheimer Analyst forecast on DE:LGDN
Leland Gershell
Oppenheimer
Oppenheimer
€290.06
Buy
22.90%
Upside
Reiterated
08/07/26
Ligand Pharma (LGND) Gets a Buy from Oppenheimer
Benchmark Co. Analyst forecast on DE:LGDN
Robert Wasserman
Benchmark Co.
Benchmark Co.
€244.68→€298.06
Buy
26.30%
Upside
Reiterated
07/16/26
Ligand price target raised to $335 from $275 at BenchmarkLigand price target raised to $335 from $275 at Benchmark
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on DE:LGDN
Glen Santangelo
Barclays
Barclays
€306.96
Buy
30.07%
Upside
Initiated
09/25/26
Analysts Offer Insights on Healthcare Companies: Ligand Pharma (NASDAQ: LGND), Natera (NASDAQ: NTRA) and Aveanna Healthcare Holdings (NASDAQ: AVAH)
H.C. Wainwright Analyst forecast on DE:LGDN
Joseph Pantginis
H.C. Wainwright
H.C. Wainwright
€318.53
Buy
34.97%
Upside
Reiterated
09/24/26
Wainwright sees upside in Ligand after new CAR-T investment in AvenCell Wainwright sees upside in Ligand after new CAR-T investment in AvenCell
Craig-Hallum Analyst forecast on DE:LGDN
Matt Hewitt
Craig-Hallum
Craig-Hallum
―
Buy
―
Assigned
09/24/26
Analysts' Top Healthcare Picks: Ligand Pharma (LGND), Mediwound (MDWD)
Citi Analyst forecast on DE:LGDN
Yigal Nochomovitz
Citi
Citi
€347→€353.23
Buy
49.67%
Upside
Reiterated
09/23/26
Ligand price target raised to $397 from $390 at CitiLigand price target raised to $397 from $390 at Citi
Stifel Nicolaus Analyst forecast on DE:LGDN
Annabel Samimy
Stifel Nicolaus
Stifel Nicolaus
―
Buy
―
Reiterated
09/22/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (NASDAQ: AMGN), Ligand Pharma (NASDAQ: LGND) and Compass Therapeutics (NASDAQ: CMPX)
Bank of America Securities Analyst forecast on DE:LGDN
Jason Zemansky
Bank of America Securities
Bank of America Securities
€345.22
Buy
46.28%
Upside
Reiterated
09/22/26
Analyst Reiterates Buy on Ligand as Ryjunea Royalty Deal Highlights Disciplined Capital Deployment and Supports Unchanged $388 Price Target
RBC Capital Analyst forecast on DE:LGDN
Douglas Miehm
RBC Capital
RBC Capital
€306.96
Buy
30.07%
Upside
Reiterated
08/09/26
Ligand Pharma (LGND) Gets a Buy from RBC Capital
Oppenheimer Analyst forecast on DE:LGDN
Leland Gershell
Oppenheimer
Oppenheimer
€290.06
Buy
22.90%
Upside
Reiterated
08/07/26
Ligand Pharma (LGND) Gets a Buy from Oppenheimer
Benchmark Co. Analyst forecast on DE:LGDN
Robert Wasserman
Benchmark Co.
Benchmark Co.
€244.68→€298.06
Buy
26.30%
Upside
Reiterated
07/16/26
Ligand price target raised to $335 from $275 at BenchmarkLigand price target raised to $335 from $275 at Benchmark
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
MDWDMediwound
OVIDOvid Therapeutics
IMUXImmunic
ASNDAscendis Pharma
AORTArtivion
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ligand Pharma

3 Months
Joseph PantginisH.C. Wainwright
Success Rate
8/10 ratings generated profit
80%
Average Return
+16.81%
Copying Joseph Pantginis's trades and holding each position for 3 Months would result in 80.00% of your transactions generating a profit, with an average return of +16.81% per trade.
1 Year
Joseph PantginisH.C. Wainwright
Success Rate
10/10 ratings generated profit
100%
Average Return
+51.02%
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +51.02% per trade.
2 Years
Joseph PantginisH.C. Wainwright
Success Rate
10/10 ratings generated profit
100%
Average Return
+67.17%
Copying Joseph Pantginis's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +67.17% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

LGDN Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
0
0
0
0
0
Buy
19
16
20
24
16
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
19
16
20
24
16
In the current month, LGDN has received 16 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. LGDN average Analyst price target in the past 3 months is 317.00.
Each month's total comprises the sum of three months' worth of ratings.

LGDN Financial Forecast

LGDN Earnings Forecast

Next quarter’s earnings estimate for LGDN is €2.06 with a range of €1.72 to €2.22. The previous quarter’s EPS was €2.11. LGDN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year LGDN has Performed in-line its overall industry.
Next quarter’s earnings estimate for LGDN is €2.06 with a range of €1.72 to €2.22. The previous quarter’s EPS was €2.11. LGDN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year LGDN has Performed in-line its overall industry.

LGDN Sales Forecast

Next quarter’s sales forecast for LGDN is €69.52M with a range of €58.38M to €81.78M. The previous quarter’s sales results were €56.80M. LGDN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year LGDN has Performed in-line its overall industry.
Next quarter’s sales forecast for LGDN is €69.52M with a range of €58.38M to €81.78M. The previous quarter’s sales results were €56.80M. LGDN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year LGDN has Performed in-line its overall industry.

LGDN Stock Forecast FAQ

What is DE:LGDN’s average 12-month price target, according to analysts?
Based on analyst ratings, Ligand Pharma’s 12-month average price target is 317.00.
    What is DE:LGDN’s upside potential, based on the analysts’ average price target?
    Ligand Pharma has 34.32% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Ligand Pharma a Buy, Sell or Hold?
          Ligand Pharma has a consensus rating of Strong Buy, which is based on 9 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Ligand Pharma’s share price target?
            The average share price target for Ligand Pharma is 317.00. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €353.23 ,and the lowest forecast is €290.06. The average share price target represents 34.32% Increase from the current price of €236.
              What do analysts say about Ligand Pharma?
              Ligand Pharma’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.
                How can I buy shares of Ligand Pharma?
                To buy shares of DE:LGDN, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.